Pitolisant 相關新聞

← 返回新聞總覽


Pitolisant 目前有 0 則相關新聞報導,預測適應症 20 個。

本頁整合 Pitolisant 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).
  • 證據等級:L5
  • 預測適應症(20 個):
    • insomnia (disease)(99.7%)
    • attention deficit-hyperactivity disorder(99.4%)
    • faciodigitogenital syndrome(99.3%)
    • X-linked adrenoleukodystrophy(99.0%)
    • disorder of peroxisomal alpha-, beta- and omega-oxidation(98.9%)
    • ACBD5 deficiency(98.7%)
    • Creutzfeldt-Jakob disease(98.5%)
    • narcolepsy-cataplexy syndrome(98.5%)
    • narcolepsy(98.4%)
    • narcolepsy, susceptibility to(98.2%)
    • megaconial type congenital muscular dystrophy(97.6%)
    • hypersomnia (disease)(97.0%)
    • Balo concentric sclerosis(96.9%)
    • circadian rhythm sleep disorder(96.7%)
    • chondromyxoid fibroma(96.6%)
    • narcolepsy without cataplexy(95.0%)
    • variably protease-sensitive prionopathy(94.8%)
    • central nervous system disease(94.8%)
    • attention deficit hyperactivity disorder, inattentive type(94.5%)
    • Wernicke-Korsakoff syndrome(93.7%)

查看完整藥物報告 →

相關新聞(0 則)

目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。

免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.